Effect of DPP4 Inhibitor on the Treatment of Type 2 Diabetes Patients with Poor Blood Glucose Control and Its Influence on Complex Non-Fatal Cardiovascular Events
Objective To investigate the effect of dipeptidyl peptidase 4 ( DPP4 ) inhibitor on blood glucose control and the incidence of combined non-fatal cardiovascular events in type 2 diabetes patients with poor response to metformin+acarbose treatment.Methods A total of 130 cases of T2DM patients who responded poorly to metformin+acarbose in the Endocrinology Department of the First Mobile Corps Hospital of People's Armed Police and the Second Mobile Corps Hospital of People's Armed Police from February 2021 to February 2023 were selected as the study subjects.They were randomly divided into the DPP4 group ( metformin+acarbose+DPP4 inhibitor ) and the insulin group ( metformin+acarbose+insulin ) using a random number table,with 65 patients in each group.All patients were continuously treated and observed for 12 months.Results The incidence of non-fatal cardiovascular events in the DPP4 group was significantly lower than that in the insulin group,he difference was statistically significant.( P<0.05 ) .Post-treatment fasting blood glucose,2-hour postprandial blood glucose,glycated hemoglobin,insulin resistance index,triglycerides,total cholesterol,malondialdehyde ( MDA ),lipid peroxidation,and reactive oxygen species ( ROS ) levels were reduced in both groups ( P<0.05 ),with MDA and ROS levels in the DPP4 group being significantly lower than in the insulin group ( P<0.05 ) .High-density lipoprotein cholesterol and glutathione peroxidase ( GSH-Px ) levels were significantly increased in both groups after treatment ( P<0.05 ),and GSH-Px levels in the DPP4 group were higher than those in the insulin group ( P<0.05 ) .Conclusion The efficacy of DPP4 inhibitors combined with metformin and acarbose in T2DM patients with poor blood glucose control is similar to that of insulin.However,the former is more effective in improving oxidative stress and reducing the incidence of non-fatal cardiovascular events.
万方数据
维普
